REFERENCES
1. Brims F. Epidemiology and clinical aspects of malignant pleural mesothelioma. Cancers. 2021;13:4194.
2. Asciak R, George V, Rahman NM. Update on biology and management of mesothelioma. Eur Respir Rev. 2021;30:200226.
3. Suarez JS, Novelli F, Goto K, et al. HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma. Proc Natl Acad Sci USA. 2023;120:e2307999120.
4. Carbone M, Minaai M, Takinishi Y, Pagano I, Yang H. Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma. J Transl Med. 2023;21:749.
5. Carbone M, Minaai M, Kittaneh M, et al. Clinical and pathologic phenotyping of mesotheliomas developing in carriers of germline BAP1 mutations. J Thorac Oncol. 2025;20:1683-98.
6. Novelli F, Bononi A, Wang Q, et al. BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene × environment interaction with asbestos. Proc Natl Acad Sci USA. 2021;118:e2111946118.
7. Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification. J Thorac Oncol. 2022;17:608-22.
8. Zhang AL, Hsu ML. Immunotherapy advances in pleural mesothelioma. Ther Adv Med Oncol. 2026;18:17588359261420028.
9. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-44.
10. Cardillo G, Waller D, Tenconi S, Di Noia V, Ricciardi S. Malignant pleural mesothelioma: a 2025 update. J Clin Med. 2025;14:1004.
11. Wolf AS, Flores RM. Updates in staging and management of malignant pleural mesothelioma. Surg Oncol Clin N Am. 2020;29:603-12.
12. Baas P, Daumont MJ, Lacoin L, et al. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: a nationwide CAS registry analysis from the I-O Optimise initiative. Lung Cancer. 2021;162:185-93.
13. Mujoomdar AA, Tilleman TR, Richards WG, Bueno R, Sugarbaker DJ. Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: Result in a cohort of 203 resection specimens. J Thorac Cardiovasc Surg. 2010;140:352-5.
14. Canino C, Mori F, Cambria A, et al. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene. 2011;31:3148-63.
15. Cioce M, Canino C, Pass H, Blandino G, Strano S, Fazio VM. Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma. J Exp Clin Cancer Res. 2021;40:344.
17. Chiurchiù V, Leuti A, Maccarrone M. Bioactive lipids and chronic inflammation: managing the fire within. Front Immunol. 2018;9:38.
18. Serhan CN, Bäck M, Chiurchiù V, et al. ; the International Lipids in Parenteral Nutrition Summit 2022 Experts. Expert consensus report on lipid mediators: role in resolution of inflammation and muscle preservation. FASEB J. 2024;38:e23699.
19. Lavy M, Gauttier V, Poirier N, Barillé-Nion S, Blanquart C. Specialized pro-resolving mediators mitigate cancer-related inflammation: role of tumor-associated macrophages and therapeutic opportunities. Front Immunol. 2021;12:702785.
20. Fishbein A, Hammock BD, Serhan CN, Panigrahy D. Carcinogenesis: failure of resolution of inflammation? Pharmacol Ther. 2021;218:107670.
21. Shum M, London CM, Briottet M, et al. CF patients’ airway epithelium and sex contribute to biosynthesis defects of pro-resolving lipids. Front Immunol. 2022;13:915261.
22. Obacz J, Valer JA, Nibhani R, et al. Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs in vitro models of mesothelioma. Eur Respir J. 2024;63:2300143.
23. Serhan CN, Gupta SK, Perretti M, et al. The Atlas of inflammation resolution (AIR). Mol Aspects Med. 2020;74:100894.
24. Hoch M, Rauthe J, Cesnulevicius K, et al. Cell-type-specific gene regulatory networks of pro-inflammatory and pro-resolving lipid mediator biosynthesis in the immune system. Int J Mol Sci. 2023;24:4342.
25. Giotti B, Dolasia K, Zhao W, et al. Single-cell view of tumor microenvironment gradients in pleural mesothelioma. Cancer Discov. 2024;2262:78.
26. Nguyen AL, Facey COB, Boman BM. The significance of aldehyde dehydrogenase 1 in cancers. Int J Mol Sci. 2024;26:251.
27. Milosevic V, Kopecka J, Salaroglio IC, et al. Wnt/IL‐1β/IL‐8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. Int J Cancer. 2020;146:192-207.
28. Magrassi L, Pinton G, Luzzi S, et al. A new vista of aldehyde dehydrogenase 1A3 (ALDH1A3): new specific inhibitors and activity-based probes targeting ALDH1A3 dependent pathways in glioblastoma, mesothelioma and other cancers. Cancers. 2024;16:2397.
